These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16336685)

  • 1. TRIPS, the Doha Declaration and increasing access to medicines: policy options for Ghana.
    Cohen JC; Gyansa-Lutterodt M; Torpey K; Esmail LC; Kurokawa G
    Global Health; 2005 Dec; 1():17. PubMed ID: 16336685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines?
    Kerry VB; Lee K
    Global Health; 2007 May; 3():3. PubMed ID: 17524147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation.
    McGIVERN L
    Milbank Q; 2023 Dec; 101(4):1280-1303. PubMed ID: 37646392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing legal and political barriers to global pharmaceutical access: options for remedying the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the imposition of TRIPS-plus standards.
    Cohen-Kohler JC; Forman L; Lipkus N
    Health Econ Policy Law; 2008 Jul; 3(Pt 3):229-56. PubMed ID: 18634618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing the effect of TRIPS on availability of priority vaccines.
    Milstien J; Kaddar M
    Bull World Health Organ; 2006 May; 84(5):360-5. PubMed ID: 16710544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.
    't Hoen EF; Veraldi J; Toebes B; Hogerzeil HV
    Bull World Health Organ; 2018 Mar; 96(3):185-193. PubMed ID: 29531417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
    Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
    Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WTO ministerial conference adopts declaration on TRIPS and public health.
    Elliott R
    Can HIV AIDS Policy Law Rev; 2002 Mar; 6(3):50-2. PubMed ID: 14979260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trade, TRIPS, and pharmaceuticals.
    Smith RD; Correa C; Oh C
    Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canada's implementation of the Paragraph 6 Decision: is it sustainable public policy?
    Cohen-Kohler JC; Esmail LC; Cosio AP
    Global Health; 2007 Dec; 3():12. PubMed ID: 18062821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Affordability versus innovation: Is compulsory licensing the solution?
    Pandey E; Paul SB
    Int J Risk Saf Med; 2019; 30(4):233-247. PubMed ID: 31658067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the impact of intellectual property rules on access to medicines? A systematic review.
    Tenni B; Moir HVJ; Townsend B; Kilic B; Farrell AM; Keegel T; Gleeson D
    Global Health; 2022 Apr; 18(1):40. PubMed ID: 35428250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRIPS and the global pharmaceutical market.
    Barton JH
    Health Aff (Millwood); 2004; 23(3):146-54. PubMed ID: 15160812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of intellectual property rights in treatment access: challenges and solutions.
    't Hoen E; Passarelli CA
    Curr Opin HIV AIDS; 2013 Jan; 8(1):70-4. PubMed ID: 23201855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poverty, health & intellectual property rights with special reference to India.
    Satyanarayana K; Srivastava S
    Indian J Med Res; 2007 Oct; 126(4):390-406. PubMed ID: 18032814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patents and access to drugs in developing countries: an ethical analysis.
    Sterckx S
    Dev World Bioeth; 2004 May; 4(1):58-75. PubMed ID: 15086374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Balancing public health, trade and intellectual monopoly privileges: recent Australian IP legislation and the TPPA.
    Vines T; Crow K; Faunce T
    J Law Med; 2012 Dec; 20(2):280-94. PubMed ID: 23431847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Driving a decade of change: HIV/AIDS, patents and access to medicines for all.
    Hoen E'; Berger J; Calmy A; Moon S
    J Int AIDS Soc; 2011 Mar; 14():15. PubMed ID: 21439089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Legal and policy foundations for global generic competition: Promoting affordable drug pricing in developing societies.
    Zapatero Miguel P
    Glob Public Health; 2015; 10(8):901-16. PubMed ID: 25737069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Canada and access to medicines in developing countries: intellectual property rights first.
    Lexchin J
    Global Health; 2013 Sep; 9():42. PubMed ID: 24007595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.